Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

Inclusion Criteria: * Diagnosis of GBM, histologically or cytologically confirmed. * Newly-diagnosed subjects prior to beginning first-line conventional therapy. * Male or female subjects 18 years of age or older. * Ability to understand and willingness to sign a written informed consent document. * Ability and consent to comply with completion of a patient diary. * Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) with conventional techniques or as ≥10 mm (≥1 cm) with spiral CT scan, MRI, or calipers by clinical exam. * Allowable type and amount of prior therapy and medication * ECOG performance status ≤2 (KPS ≥60%, see Appendix A). * Life expectancy of greater than 6 months * Subjects must have adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment: * Total bilirubin \< 1.5 x the upper limit of normal (ULN). * Alanine transaminase (ALT) and aspartate aminotransferase (AST) \< 2.5 xULN (\< 5 x ULN for subjects with liver involvement of their cancer). * Alkaline phosphatase limit \< 2.5 x ULN (\<5 x ULN for subjects with liver involvement of their cancer) * Serum creatinine \< 1.5 x the ULN. Glomerular filtration rate (GFR) ≥ 30 ml/min/1.73 m2 according to the MDRD (Modified diet in renal diseas…